Eledon pharmaceuticals reports fourth quarter and full year 2023 operating and financial results

Enrolled 12 participants in phase 2 bestow trial evaluating tegoprubart for the prevention of kidney rejection tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human additional data from 11 participants in phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function irvine, calif., march 28, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent business highlights.
ELDN Ratings Summary
ELDN Quant Ranking